![]() |
|
![]() |
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
Array BioPharma |
Information provided by: | Array BioPharma |
ClinicalTrials.gov Identifier: | NCT00085787 |
The purpose of this study is to assess the tolerability of ARRY-142886 in patients with advanced solid malignancies that have failed standard therapy or for whom no standard therapy exists and determine the maximum tolerated dose as defined by significant dose limiting toxicity.
Condition | Intervention | Phase |
Cancer |
Drug: ARRY-142886 |
Phase I |
MedlinePlus related topics: | Cancer |
ChemIDplus related topics: | ARRY 142886 |
Study Type: | Interventional |
Study Design: | Treatment, Open Label, Pharmacokinetics/Dynamics Study |
Official Title: | A Phase I, Open-Label, Multiple Dose Study to Assess the Tolerability, Pharmacokinetics and Pharmacodynamics of ARRY-142886 Given on a Daily Oral Regime in Subjects With Advanced Solid Malignancies |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Colorado | |||||
University of Colorado Cancer Center, Anschutz Cancer Center | |||||
Aurora, Colorado, United States, 80010 | |||||
United States, Minnesota | |||||
Mayo Clinic Rochester | |||||
Rochester, Minnesota, United States, 55905 | |||||
United States, Pennsylvania | |||||
Fox Chase Cancer Center | |||||
Philadelphia, Pennsylvania, United States, 19111 |
Array BioPharma |
Study ID Numbers: | ARRY-0401 |
First Received: | June 14, 2004 |
Last Updated: | July 12, 2007 |
ClinicalTrials.gov Identifier: | NCT00085787 |
Health Authority: | United States: Food and Drug Administration |
![]() |